How I approach the treatment of thrombotic complications in patients with myeloproliferative neoplasms

2.

James

C

,

Ugo

V

,

Le Couédic

J-P

, et al.

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

.

Nature

.

2005

;

434

:

5

.

3.

Kralovics

R

,

Passamonti

F

,

Buser

AS

, et al.

A gain-of-function mutation of JAK2 in myeloproliferative disorders

.

N Engl J Med

.

2005

;

352

(

17

):

1779

-

1790

.

4.

Baxter

EJ

,

Scott

LM

,

Campbell

PJ

, et al.

Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders

.

Lancet

.

2005

;

365

(

9464

):

1054

-

1061

.

5.

Levine

RL

,

Wadleigh

M

,

Cools

J

, et al.

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

.

Cancer Cell

.

2005

;

7

(

4

):

387

-

397

.

6.

Klampfl

T

,

Gisslinger

H

,

Harutyunyan

AS

, et al.

Somatic mutations of calreticulin in myeloproliferative neoplasms

.

N Engl J Med

.

2013

;

369

(

25

):

2379

-

2390

.

7.

Nangalia

J

,

Massie

CE

,

Baxter

EJ

, et al.

Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2

.

N Engl J Med

.

2013

;

369

(

25

):

2391

-

2405

.

8.

Pikman

Y

,

Lee

BH

,

Mercher

T

, et al.

MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia

.

PLoS Med

.

2006

;

3

(

7

):

e270

.

9.

Hultcrantz

M

,

Björkholm

M

,

Dickman

PW

, et al.

Risk for arterial and venous thrombosis in patients with myeloproliferative neoplasms: a population-based cohort study

.

Ann Intern Med

.

2018

;

168

(

5

):

317

.

10.

Rungjirajittranon

T

,

Owattanapanich

W

,

Ungprasert

P

,

Siritanaratkul

N

,

Ruchutrakool

T

.

A systematic review and meta-analysis of the prevalence of thrombosis and bleeding at diagnosis of Philadelphia-negative myeloproliferative neoplasms

.

BMC Cancer

.

2019

;

19

(

1

):

184

.

11.

Gerds

AT

,

Mesa

RA

,

Burke

JM

, et al.

Association between elevated white blood cell counts and thrombotic events in polycythemia vera: analysis from REVEAL

.

Blood

.

2024

;

143

(

16

):

1646

-

1655

.

12.

Hernández-Boluda

J-C

,

Pastor-Galán

I

,

Arellano-Rodrigo

E

, et al.

Predictors of thrombosis and bleeding in 1613 myelofibrosis patients from the Spanish registry of myelofibrosis

.

Br J Haematol

.

2022

;

199

(

4

):

529

-

538

.

13.

Barbui

T

,

Carobbio

A

,

Cervantes

F

, et al.

Thrombosis in primary myelofibrosis: incidence and risk factors

.

Blood

.

2010

;

115

(

4

):

778

-

782

.

14.

Buxhofer-Ausch

V

,

Gisslinger

H

,

Thiele

J

, et al.

Leukocytosis as an important risk factor for arterial thrombosis in WHO-defined early/prefibrotic myelofibrosis: an international study of 264 patients

.

Am J Hematol

.

2012

;

87

(

7

):

669

-

672

.

15.

Elliott

MA

,

Pardanani

A

,

Lasho

TL

,

Schwager

SM

,

Tefferi

A

.

Thrombosis in myelofibrosis: prior thrombosis is the only predictive factor and most venous events are provoked

.

Haematologica

.

2010

;

95

(

10

):

1788

-

1791

.

16.

Carobbio

A

,

Vannucchi

AM

,

Rumi

E

, et al.

Survival expectation after thrombosis and overt-myelofibrosis in essential thrombocythemia and prefibrotic myelofibrosis: a multistate model approach

.

Blood Cancer J

.

2023

;

13

(

1

):

115

.

17.

Marchioli

R

,

Finazzi

G

,

Landolfi

R

, et al.

Vascular and neoplastic risk in a large cohort of patients with polycythemia vera

.

J Clin Oncol

.

2005

;

23

(

10

):

2224

-

2232

.

18.

Tefferi

A

,

Rumi

E

,

Finazzi

G

, et al.

Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study

.

Leukemia

.

2013

;

27

(

9

):

1874

-

1881

.

19.

Bonicelli

G

,

Abdulkarim

K

,

Mounier

M

, et al.

Leucocytosis and thrombosis at diagnosis are associated with poor survival in polycythaemia vera: a population-based study of 327 patients

.

Br J Haematol

.

2013

;

160

(

2

):

251

-

254

.

20.

Guy

A

,

Poisson

J

,

James

C

.

Pathogenesis of cardiovascular events in BCR-ABL1-negative myeloproliferative neoplasms

.

Leukemia

.

2021

:

1

-

21

.

21.

Wolach

O

,

Sellar

RS

,

Martinod

K

, et al.

Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms

.

Sci Transl Med

.

2018

;

10

(

436

).

22.

Guy

A

,

Garcia

G

,

Gourdou-Latyszenok

V

, et al.

Platelets and neutrophils cooperate to induce increased neutrophil extracellular trap formation in JAK2V617F myeloproliferative neoplasms

.

J Thromb Haemostasis

.

2024

;

22

(

1

):

172

-

187

.

23.

Farina

M

,

Russo

D

,

Hoffman

R

.

The possible role of mutated endothelial cells in myeloproliferative neoplasms

.

Haematologica

.

2021

;

106

(

11

):

2813

-

2823

.

24.

Smalberg

JH

,

Arends

LR

,

Valla

DC

, et al.

Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis

.

Blood

.

2012

;

120

(

25

):

4921

-

4928

.

25.

Kiladjian

J-J

,

Cassinat

B

.

Myeloproliferative neoplasms and splanchnic vein thrombosis: Contemporary diagnostic and therapeutic strategies

.

Am J Hematol

.

2023

;

98

(

5

):

794

-

800

.

26.

Rumi

E

,

Pietra

D

,

Ferretti

V

, et al.

JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes

.

Blood

.

2014

;

123

(

10

):

1544

-

1551

.

27.

Rumi

E

,

Pietra

D

,

Pascutto

C

, et al.

Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis

.

Blood

.

2014

;

124

(

7

):

1062

-

1069

.

28.

Rotunno

G

,

Mannarelli

C

,

Guglielmelli

P

, et al.

Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia

.

Blood

.

2014

;

123

(

10

):

1552

-

1555

.

29.

Finazzi

MC

,

Carobbio

A

,

Cervantes

F

, et al.

CALR mutation, MPL mutation and triple negativity identify patients with the lowest vascular risk in primary myelofibrosis

.

Leukemia

.

2015

;

29

(

5

):

1209

-

1210

.

30.

Barbui

T

,

Finazzi

G

,

Carobbio

A

, et al.

Development and validation of an international prognostic score of thrombosis in world health organization–essential thrombocythemia (IPSET-thrombosis)

.

Blood

.

2012

;

120

(

26

):

5128

-

5133

.

31.

Barbui

T

,

Vannucchi

AM

,

Buxhofer-Ausch

V

, et al.

Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia

.

Blood Cancer J

.

2015

;

5

(

11

):

e369

.

32.

Pasquer

H

,

Daltro de Oliveira

R

,

Vasseur

L

, et al.

Distinct clinico-molecular arterial and venous thrombosis scores for myeloproliferative neoplasms risk stratification

.

Leukemia

.

2024

;

38

(

2

):

326

-

339

.

33.

Alvarez-Larrán

A

,

Cuevas

B

,

Velez

P

, et al.

Application of IPSET-thrombosis in 1366 patients prospectively followed from the Spanish registry of essential thrombocythemia

.

Hemasphere

.

2023

;

7

(

8

):

e936

.

34.

Guglielmelli

P

,

Carobbio

A

,

Rumi

E

, et al.

Validation of the IPSET score for thrombosis in patients with prefibrotic myelofibrosis

.

Blood Cancer J

.

2020

;

10

(

2

):

1

-

8

.

35.

Carobbio

A

,

Finazzi

G

,

Antonioli

E

, et al.

Thrombocytosis and leukocytosis interaction in vascular complications of essential thrombocythemia

.

Blood

.

2008

;

112

(

8

):

3135

-

3137

.

36.

Campbell

PJ

,

MacLean

C

,

Beer

PA

, et al.

Correlation of blood counts with vascular complications in essential thrombocythemia: analysis of the prospective PT1 cohort

.

Blood

.

2012

;

120

(

7

):

1409

-

1411

.

37.

Marchetti

M

,

Vannucchi

AM

,

Griesshammer

M

, et al.

Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations

.

The Lancet Haematology

.

2022

;

9

(

4

):

e301

-

e311

.

38.

Tefferi

A

.

Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management

.

Am J Hematol

.

2023

;

98

(

5

):

801

-

821

.

39.

De Stefano

V

,

Rossi

E

,

Carobbio

A

, et al.

Hydroxyurea prevents arterial and late venous thrombotic recurrences in patients with myeloproliferative neoplasms but fails in the splanchnic venous district. Pooled analysis of 1500 cases

.

Blood Cancer J

.

2018

;

8

(

11

):

112

.

40.

Bewersdorf

JP

,

Giri

S

,

Wang

R

, et al.

Interferon alpha therapy in essential thrombocythemia and polycythemia vera - a systematic review and meta-analysis

.

Leukemia

.

2021

;

35

(

6

):

1643

-

1660

.

41.

Gisslinger

H

,

Klade

C

,

Georgiev

P

, et al.

Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study

.

The Lancet Haematology

.

2020

;

7

(

3

):

e196

-

e208

.

42.

Harrison

CN

,

Nangalia

J

,

Boucher

R

, et al.

Ruxolitinib versus best available therapy for polycythemia vera intolerant or resistant to hydroxycarbamide in a randomized trial

.

J Clin Oncol

.

2023

;

41

(

19

):

3534

-

3544

.

43.

Masciulli

A

,

Ferrari

A

,

Carobbio

A

,

Ghirardi

A

,

Barbui

T

.

Ruxolitinib for the prevention of thrombosis in polycythemia vera: a systematic review and meta-analysis

.

Blood Advances

.

2020

;

4

(

2

):

380

-

386

.

44.

Mora

B

,

Guglielmelli

P

,

Kuykendall

A

, et al.

Prediction of thrombosis in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study on 1258 patients

.

Leukemia

.

2022

;

36

(

10

):

2453

-

2460

.

45.

Harrison

CN

,

Campbell

PJ

,

Buck

G

, et al.

Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia

.

N Engl J Med

.

2005

;

353

(

1

):

33

-

45

.

46.

Gisslinger

H

,

Gotic

M

,

Holowiecki

J

, et al.

Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET study, a randomized controlled trial

.

Blood

.

2013

;

121

(

10

):

1720

-

1728

.

47.

Middeldorp

S

,

Nieuwlaat

R

,

Baumann

Kreuziger L

, et al.

American Society of Hematology 2023 guidelines for management of venous thromboembolism: thrombophilia testing

.

Blood Advances

.

2023

;

7

(

22

):

7101

-

7138

.

48.

Ortel

TL

,

Neumann

I

,

Ageno

W

, et al.

American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism

.

Blood Advances

.

2020

;

4

(

19

):

4693

-

4738

.

49.

Khan

F

,

Rahman

A

,

Carrier

M

, et al.

Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis

.

BMJ

.

2019

;

366

:

l4363

.

50.

Girardi

L

,

Wang

T-F

,

Ageno

W

,

Carrier

M

.

Updates in the incidence, pathogenesis, and management of cancer and venous thromboembolism

.

Arterioscler Thromb Vasc Biol

.

2023

;

43

(

6

):

824

-

831

.

51.

Lyman

GH

,

Carrier

M

,

Ay

C

, et al.

American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer

.

Blood Advances

.

2021

;

5

(

4

):

927

-

974

.

52.

Barbui

T

,

Carobbio

A

,

De Stefano

V

.

Thrombosis in myeloproliferative neoplasms during cytoreductive and antithrombotic drug treatment

.

Research and Practice in Thrombosis and Haemostasis

.

2022

;

6

(

1

):

e12657

.

53.

Ferrari

A

,

Carobbio

A

,

Masciulli

A

, et al.

Clinical outcomes under hydroxyurea treatment in polycythemia vera: a systematic review and meta-analysis

.

Haematologica

.

2019

;

104

(

12

):

2391

-

2399

.

54.

Stevens

SM

,

Woller

SC

,

Bauer

KA

, et al.

Guidance for the evaluation and treatment of hereditary and acquired thrombophilia

.

J Thromb Thrombolysis

.

2016

;

41

:

154

-

164

.

55.

Stevens

SM

,

Woller

SC

,

Kreuziger

LB

, et al.

Antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report

.

Chest

.

2021

;

160

(

6

):

e545

-

e608

.

56.

Decousus

H

,

Prandoni

P

,

Mismetti

P

, et al.

Fondaparinux for the treatment of superficial-vein thrombosis in the legs

.

N Engl J Med

.

2010

;

363

(

13

):

1222

-

1232

.

57.

Kakkos

SK

,

Gohel

M

,

Baekgaard

N

, et al.

Editor’s choice - European Society for Vascular Surgery (ESVS) 2021 clinical practice guidelines on the management of venous thrombosis

.

Eur J Vasc Endovasc Surg

.

2021

;

61

(

1

):

9

-

82

.

58.

Barco

S

,

Pomero

F

,

Di Minno

MND

, et al.

Clinical course of patients with symptomatic isolated superficial vein thrombosis: the ICARO follow-up study

.

J Thromb Haemostasis

.

2017

;

15

(

11

):

2176

-

2183

.

59.

Galanaud

J-P

,

Blaise

S

,

Sevestre

M-A

, et al.

Long-term outcomes of isolated superficial vein thrombosis in patients with active cancer

.

Thromb Res

.

2018

;

171

:

179

-

186

.

60.

De Stefano

V

,

Ruggeri

M

,

Cervantes

F

, et al.

High rate of recurrent venous thromboembolism in patients with myeloproliferative neoplasms and effect of prophylaxis with vitamin K antagonists

.

Leukemia

.

2016

;

30

(

10

):

2032

-

2038

.

61.

Farge

D

,

Frere

C

,

Connors

JM

, et al.

2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19

.

Lancet Oncol

.

2022

;

23

(

7

):

e334

-

e347

.

62.

Ianotto

J-C

,

Couturier

M-A

,

Galinat

H

, et al.

Administration of direct oral anticoagulants in patients with myeloproliferative neoplasms

.

Int J Hematol

.

2017

;

106

(

4

):

517

-

521

.

63.

Fedorov

K

,

Goel

S

,

Kushnir

M

,

Billett

HH

.

Thrombosis in myeloproliferative neoplasms: treatment outcomes of direct oral anticoagulants and vitamin K antagonists

.

Research and Practice in Thrombosis and Haemostasis

.

2021

;

5

(

6

):

e12574

.

64.

Serrao

A

,

Breccia

M

,

Napolitano

M

, et al.

A multicenter real-life study on anticoagulant treatment with direct oral anticoagulants in patients with Ph-negative myeloproliferative neoplasms

.

Am J Hematol

.

2020

;

95

(

12

):

E329

-

E332

.

65.

Huenerbein

K

,

Sadjadian

P

,

Becker

T

, et al.

Direct oral anticoagulants (DOAC) for prevention of recurrent arterial or venous thromboembolic events (ATE/VTE) in myeloproliferative neoplasms

.

Ann Hematol

.

2021

;

100

(

8

):

2015

-

2022

.

66.

Barbui

T

,

De Stefano

V

,

Carobbio

A

, et al.

Direct oral anticoagulants for myeloproliferative neoplasms: results from an international study on 442 patients

.

Leukemia

.

2021

;

35

(

10

):

2989

-

2993

.

67.

Larsen

T

,

Garresori

H

,

Brekke

J

, et al.

Low dose apixaban as secondary prophylaxis of venous thromboembolism in cancer patients – 30 months follow-up

.

J Thromb Haemostasis

.

2022

;

20

(

5

):

1166

-

1181

.

68.

De Stefano

V

,

Ghirardi

A

,

Masciulli

A

, et al.

Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer: a case-control study

.

Blood

.

2020

;

135

(

5

):

381

-

386

.

69.

Sekhar

M

,

McVinnie

K

,

Burroughs

AK

.

Splanchnic vein thrombosis in myeloproliferative neoplasms

.

Br J Haematol

.

2013

;

162

(

6

):

730

-

747

.

70.

Stefano

VD

,

Qi

X

,

Betti

S

,

Rossi

E

.

Splanchnic vein thrombosis and myeloproliferative neoplasms: molecular-driven diagnosis and long-term treatment

.

Thromb Haemost

.

2016

;

115

(

02

):

240

-

249

.

71.

How

J

,

Trinkaus

KM

,

Oh

ST

.

Distinct clinical, laboratory and molecular features of myeloproliferative neoplasm patients with splanchnic vein thrombosis

.

Br J Haematol

.

2018

;

183

(

2

):

310

-

313

.

72.

De Stefano

V

,

Vannucchi

AM

,

Ruggeri

M

, et al.

Splanchnic vein thrombosis in myeloproliferative neoplasms: risk factors for recurrences in a cohort of 181 patients

.

Blood Cancer J

.

2016

;

6

(

11

):

e493

.

73.

Plessier

A

,

Goria

O

,

Cervoni

JP

, et al.

Rivaroxaban prophylaxis in noncirrhotic portal vein thrombosis

.

NEJM Evidence

.

2022

;

1

(

12

).

74.

Curto-Garcia

N

,

Doyle

AJ

,

Breen

KA

, et al.

Outcomes of patients receiving direct oral anticoagulants for myeloproliferative neoplasm-associated venous thromboembolism in a large tertiary centre in the UK

.

Br J Haematol

.

2020

;

189

(

3

):

e79

-

e81

.

75.

Tremblay

D

,

Vogel

AS

,

Moshier

E

, et al.

Outcomes of splanchnic vein thrombosis in patients with myeloproliferative neoplasms in a single center experience

.

Eur J Haematol

.

2020

;

104

(

1

):

72

-

73

.

76.

Hoekstra

J

,

Bresser

EL

,

Smalberg

JH

, et al.

Long-term follow-up of patients with portal vein thrombosis and myeloproliferative neoplasms

.

J Thromb Haemostasis

.

2011

;

9

(

11

):

2208

-

2214

.

77.

Sant’Antonio

E

,

Guglielmelli

P

,

Pieri

L

, et al.

Splanchnic vein thromboses associated with myeloproliferative neoplasms: An international, retrospective study on 518 cases

.

Am J Hematol

.

2020

;

95

(

2

):

156

-

166

.

78.

Lavu

S

,

Szuber

N

,

Mudireddy

M

, et al.

Splanchnic vein thrombosis in patients with myeloproliferative neoplasms: The Mayo clinic experience with 84 consecutive cases

.

Am J Hematol

.

2018

;

93

(

3

):

E61

-

E64

.

79.

Finazzi

G

,

De Stefano

V

,

Barbui

T

.

Splanchnic vein thrombosis in myeloproliferative neoplasms: treatment algorithm 2018

.

Blood Cancer J

.

2018

;

8

(

7

).

80.

Galtier

J

,

Drevon

L

,

Bris

YL

, et al.

Role of red cell mass evaluation in myeloproliferative neoplasms with splanchnic vein thrombosis and normal hemoglobin value: a study of the France Intergroupe des Syndromes myeloprolifératifs

.

Haematologica

.

2024

.

81.

Maaziz

N

,

Georges

M

,

Basille

D

, et al.

The co-rebreathing method is a reliable test in determining the red cell mass: the old pots make the best soups [abstract]

.

Hemasphere

.

2023

;

7

(

Suppl

):

e993538d

.